Literature DB >> 8178970

17 beta-Estradiol attenuates voltage-dependent Ca2+ currents in A7r5 vascular smooth muscle cell line.

F Zhang1, J L Ram, P R Standley, J R Sowers.   

Abstract

Previous studies have shown that 17 beta-estradiol (beta-E2) has a direct acute inhibitory effect on vascular smooth muscle (VSM) contraction. To investigate the mechanisms underlying this phenomenon, we utilized whole cell patch-clamping techniques to study effects of beta-E2 on voltage-dependent Ca2+ channels in cultured VSM cells (VSMC). T- and L-type Ca2+ currents were characterized with ramp and pulse protocols in A7r5 cultured VSMC. T-type current, inactivated in < 100 ms, was reduced by Ba2+ and was comparatively little affected by isradipine. L-type current required higher voltages to activate, inactivated slowly, was greatly increased by Ba2+, and could be completely inhibited by 5 microM isradipine. beta-E2 (10 microM) significantly reduced peak L-type Ba2+ current and T-type Ca2+ current within 1-2 min, whereas alpha E2 (a hormonally inactive isomer of estradiol) caused significantly less reduction in both types of current. Vehicle (0.1% ethanol) had no significant effect on either current. The inhibitory effect of beta-E2 on voltage-dependent Ca2+ currents may contribute to previously demonstrated beta-E2 attenuation of VSM contraction.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8178970     DOI: 10.1152/ajpcell.1994.266.4.C975

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  37 in total

Review 1.  Low-voltage-activated ("T-Type") calcium channels in review.

Authors:  Anne Marie R Yunker; Maureen W McEnery
Journal:  J Bioenerg Biomembr       Date:  2003-12       Impact factor: 2.945

2.  Nitric oxide contributes to estrogen-induced vasodilation of the ovine uterine circulation.

Authors:  C R Rosenfeld; B E Cox; T Roy; R R Magness
Journal:  J Clin Invest       Date:  1996-11-01       Impact factor: 14.808

3.  (S)-reticuline induces vasorelaxation through the blockade of L-type Ca(2+) channels.

Authors:  Marcos Antônio A Medeiros; Xirley P Nunes; José M Barbosa-Filho; Virginia S Lemos; José F Pinho; Danilo Roman-Campos; Isac A de Medeiros; Demetrius Antonio M Araújo; Jader S Cruz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-09-30       Impact factor: 3.000

4.  Does angina vary with the menstrual cycle in women with premenopausal coronary artery disease?

Authors:  G W Lloyd; N R Patel; E McGing; A F Cooper; D Brennand-Roper; G Jackson
Journal:  Heart       Date:  2000-08       Impact factor: 5.994

5.  Estrogen, vascular estrogen receptor and hormone therapy in postmenopausal vascular disease.

Authors:  Raouf A Khalil
Journal:  Biochem Pharmacol       Date:  2013-10-04       Impact factor: 5.858

6.  Transcriptional profiling reveals elevated Sox2 in DNA polymerase ß null mouse embryonic fibroblasts.

Authors:  Jianfeng Li; Soumya Luthra; Xiao-Hong Wang; Uma R Chandran; Robert W Sobol
Journal:  Am J Cancer Res       Date:  2012-11-20       Impact factor: 6.166

7.  Potential role of estrogen in the pathobiology and prevention of Alzheimer's disease.

Authors:  Whitney Wharton; Carey E Gleason; Katelin R Lorenze; Tamara S Markgraf; Michele L Ries; Cynthia M Carlsson; Sanjay Asthana
Journal:  Am J Transl Res       Date:  2009-01-20       Impact factor: 4.060

8.  Subtype-specific estrogen receptor-mediated vasodilator activity in the cephalic, thoracic, and abdominal vasculature of female rat.

Authors:  Ossama M Reslan; Zongzhi Yin; Graciliano R A do Nascimento; Raouf A Khalil
Journal:  J Cardiovasc Pharmacol       Date:  2013-07       Impact factor: 3.105

Review 9.  Estrogenic compounds, estrogen receptors and vascular cell signaling in the aging blood vessels.

Authors:  Dia A Smiley; Raouf A Khalil
Journal:  Curr Med Chem       Date:  2009       Impact factor: 4.530

10.  Facilitation of myocardial PI3K/Akt/nNOS signaling contributes to ethanol-evoked hypotension in female rats.

Authors:  Mahmoud M El-Mas; Ming Fan; Abdel A Abdel-Rahman
Journal:  Alcohol Clin Exp Res       Date:  2009-04-09       Impact factor: 3.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.